EGFR and ovarian cancer: Antitumor therapeutics that target EGFR signaling has been developed, including gefitinib, erlotinib, and icotinib.8 High expression of EGFR is known to positively correlate with growth and progression of ovarian cancers, leading to poor prognosis in women with advanced cases.9